New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
09:47 EDTLCILannett could see decreased digoxin sales, says Craig-Hallum
Last week an article in the Journal of American College of Cardiology, or JACC, highlighted concerns regarding increased mortality for Digoxin users. Craig-Hallum said Digoxin is one of Lannett's top drugs and believes the study combined with the push-back on last year's price increase could lead to a decrease in Digoxin sales. Shares are Buy rated but the analyst is growing more cautions near-term.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
13:21 EDTLCILannett receives FDA approval for Dorzolamide HCL with Timolol
Lannett announced that it has received approval from the U.S. FDA of its Abbreviated New Drug Application for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, the therapeutic equivalent to the reference listed drug, Cosopt Ophthalmic Solution, 2%/0.5%, of Oak Pharmaceuticals, Inc.. According to IMS, for the year ended October 2014 total sales of Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5%, at Average Wholesale Price were approximately $123M.
December 8, 2014
17:34 EDTLCILannett served with subpoena in federal probe related to generic industry
Subscribe for More Information
11:30 EDTLCILeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
December 5, 2014
07:54 EDTLCILannett names Michael Bogda as president, effective December 1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use